| Literature DB >> 31627414 |
Puspo Edi Giriwono1,2, Diah Iskandriati3, Chin Ping Tan4, Nuri Andarwulan5,6.
Abstract
Sargassum is recognized both empirically and scientifically as a potential anti-inflammatory agent. Inflammation is an important response in the body that helps to overcome various challenges to body homeostasis such as microbial infections, tissue stress, and certain injuries. Excessive and uncontrolled inflammatory conditions can affect the pathogenesis of various diseases. This review aims to explore the potential of Sargassum's anti-inflammatory activity, not only in crude extracts but also in sulfated polysaccharides and purified compounds. The tropical region has a promising availability of Sargassum biomass because its climate allows for the optimal growth of seaweed throughout the year. This is important for its commercial utilization as functional ingredients for both food and non-food applications. To the best of our knowledge, studies related to Sargassum's anti-inflammatory activity are still dominated by subtropical species. Studies on tropical Sargassum are mainly focused on the polysaccharides group, though there are some other potentially bioactive compounds such as polyphenols, terpenoids, fucoxanthin, fatty acids and their derivatives, typical polar lipids, and other groups. Information on the modulation mechanism of Sargassum's bioactive compounds on the inflammatory response is also discussed here, but specific mechanisms related to the interaction between bioactive compounds and targets in cells still need to be further studied.Entities:
Keywords: Sargassum; bioactive compounds; inflammation; mechanism; tropical
Mesh:
Substances:
Year: 2019 PMID: 31627414 PMCID: PMC6835611 DOI: 10.3390/md17100590
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Studies on the anti-inflammatory activity of Sargassum crude extracts and their partitions.
| Sample | Observed Response | Tested Compound | Model | Ref. |
|---|---|---|---|---|
|
| ||||
|
Decreased serum interleukin (IL)-2, tumor necrosis factor (TNF)-α, and IL-1β production, improve wound healing rate, and elevated serum IL-4 1 Decreased nitric oxide (NO) production 2,3 | Phyto-oleic acid nanovesicles (PONVs) made by petroleum ether extract 1; water extract 2; and ethanolic precipitate of water extract 3 | Wounded streptozotocin-induced diabetic rats 1; and lipopolysaccharide (LPS)-induced RAW 264.7 2,3 | 1 [ | |
|
Decreased NO, prostaglandin E2 (PGE2), IL-6, TNF-α, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 production 1,2 Inhibition of p65 nuclear factor kappa B (NF-kB) translocation 1 Decreased ear edema volume and mastocyte infiltration 1 | Ethanol extract 1,2 | LPS-induced RAW 264.7 1,2; | 1 [ | |
|
Significant inhibition of 5-lipoxygenase (LOX), COX-1, and COX-2 in vitro 1 Inhibition of in vitro albumin denaturation 2,6 Decreased paw edema volume 3,4,5 Inhibition of red blood cells (RBC) hemolysis and proteinase activity 6 | Methanol-ethyl acetate extract 1; chloroform extract 1,3; ethanol extract 2,3; hexane extract 3, 6; methanol extract 4,5,6; butanol extract 4; and ethyl-acetate extract 6 | In vitro inhibition of 5-LOX, COX-1, and COX-2 1; albumin denaturation inhibition 2,6; carrageenan-induced rat paw edema 3,4,5; and RBC membrane stabilization and proteinase inhibition 6 | 1 [ | |
|
Decreased serum TNF-α, IL-6, and C-reactive protein (CRP) production in diabetic rats 1 Decreased paw edema volume and inflammatory exudate 2 Reduction of inflammatory cells accumulation, cell swelling, and dilated sinusoids in hepatocytes through histopathological observation 3 Decreased NO production 4 | Gold nanoparticles of water extract 1; methanol extract 2; water extract 3; and diethyl ether fraction of methanol extract 4 | Alloxan-induced diabetic Wistar rats 1; carrageenan-induced rat paw edema and peritonitis 2; acetaminophen-induced hepatotoxicity in mice 3; and LPS-induced RAW 264.7 4 | 1 [ | |
| Decreased rat paw edema volume | β-glucan extract yielded from acid and ultrasound methods | Carrageenan-induced rat ( | [ | |
|
| Decreased paw edema volume | Methanol extract; | Carrageenan-induced rat paw edema | [ |
|
| Decreased NO production 1,2 | Water extract 1; and ethanolic precipitate of water extract 2 | LPS-induced RAW 264.7 1,2 | 1 [ |
|
| Improved plasma lipid profile (plasma cholesterol, triglycerides, low density lipoprotein/LDL, and high density lipoprotein/HDL), decreased serum malondialdehyde (MDA), NO, TNF-α, and leptin production, and increased serum adiponectin level | Methanol extract (100 mg/kg) | Atherogenic diet-induced female Sprague Dawley rats | [ |
|
|
Decreased rat paw edema volume 1 Decreased serum TNF-α and intact condition of hepatocytes 2 Improvement of inflammatory condition in histopathological evaluation of liver and kidney tissue 3 Decreased production of NO and proinflammatory cytokines (TNF-α, IL-1β, and IL-6) 4 | Hexane fraction from methanol extract 1; ethanol extract 2,3; water extract 3; hexane, dichloromethane, and methanol extract 4 | Carrageenan-induced rat paw edema 1; acetaminophen-induced hepatoxicity in rat 2; high calorie diet and low dose streptozotocin-induced type II diabetes 3; and LPS-induced C8B4 microglia cells 4 | 1 [ |
|
|
Decreased rat paw edema volume 1 Inhibition of COX-1 and COX-2 activity 2 | Methanol extract 1; ethyl acetate extract 2 | Carrageenan-induced rat paw edema 1; and in vitro inhibition to COX-1 and COX-2 enzymes 2 | 1 [ |
|
| ||||
|
|
Decreased production of NO, TNF-α 1,2,4, IL-1β, and IL-6 1,2 Decreased ear edema volume 3 Suppression of iNOS expression 4 Decreased NO production and increased reactive oxygen species (ROS) scavenging activity 5 Suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression 6 Suppression of ear edema and erythema 7 Decreased production of myeloperoxidase (MPO) and enhanced production of antioxidant enzymes (superoxide dismutase (SOD)-1 and glutathion reductase) 8 | Ethanolic extract of fermented samples and its fractions 1; ethyl acetate extract 2; extract of dichloromethane, ethanol, and water 3; ethanol 70% extract 4; ethanol extract 5; and methanol extract 6,7,8 | LPS-induced RAW 264.7 1,2,5; rat ear edema 3; LPS-induced BV-2 microglial cells 4; H2O2-induced RAW 264.7 5; phorbol 12-myristate 13 acetate (PMA)-induced HT1080 6; PMA-induced mouse ear edema and erythema 7; and TNF-α stimulated human monocytic leukemia 8 | 1 [ |
|
|
Decreased production of COX-2, iNOS, pro-inflammatory cytokines, NO, and PGE2 1,2,3 Increased expression of CU/Zn- superoxide dismutase (SOD) and reduced ROS production 1 Decreased ear edema volume 4 Suppressed NO production 5,6 and reduced cytoplasmic activity 5, Decreased serum IL-4, immunoglobulin E (IgE), and TNF- Suppression of ear edema and erythema formation 8 | Ethyl acetate fraction from ethanol extract 1, hexane fraction 2; ethanol extract 3,4,7; dichloromethane extract 4; and water extract 4,5; ethanol precipitate of water extract 6; and methanol extract 8 | Ultraviolet B (UVB)-induced HaCaT keratinocytes and BALB/c mice 1; LPS-induced RAW 264.7 2,3,5, 6; rat ear edema 3,4; dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD)-like skin lesions in BALB/c mice 7; and PMA-induced mouse ear edema and erythema 8 | 1 [ |
|
|
Decreased NO, PGE2, iNOS, and COX-2 production 1,2,4 Inhibition of inhibitor kappa B (IkB) degradation 1,3 Decreased expression of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, monocyte chemoattractant protein (MCP)-1, keratinocyte chemoattractant (KC) 3,6, and MMP-9 6, and elevated heme oxygenase 1 expression 3 Inhibition of NF-kB transactivation 3,4,6, MAPKs phosphorylation, and phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) activation 4 Decreased expression of MMP-1, MMP-3, and MMP-13 4 Decreased macrophage infiltration and MCP-1 expression in epididymal tissue 5 | Ethanol extract 1,2,4; hexane fraction from ethanolic extract 3; meroterpenoid-rich extract from hexane fraction 5,6 | LPS-induced mouse peritoneal macrophage 1; LPS-induced BV-2 microglial cells and LPS-induced rat hippocampus cells 2; TNF-α-induced human umbilical vein endothelial cells (HUVECs) 3,6; IL-1β-treated SW1353 human chondrocytes 4; high fat (HF)-fed C57BL/6J mice 5; and high cholesterol diet (HCD)-fed C57BL/6J mice 6 | 1 [ |
|
|
Suppressed NO, IL-6, TNF-α, IL-1β, iNOS, and COX-2 production Decreased mitogen-activated protein kinases (MAPKs) and NF-kB activation Decreased ear edema volume | Ethanol extract | LPS-induced RAW 264.7 and rat ear edema | [ |
|
|
Suppressed ear edema formation and RBL (rat basophilic leukemia) degranulation 1 Decreased activity of phospholipase A2 (PLA2), COX-2, LOX, and hyaluronidase 1 Decreased NO 2,4 and ROS 4 production Decreased TNF-α production, and elevated production of IL-6 and IL-10 production 3 Decreased NO, iNOS, COX-2, and pro-inflammatory cytokines production via inhibition of MAPKs activation 5 Suppression of ear edema and erythema formation 6 | Administration of diethyl ether fraction percutaneously and orally 1; ethyl acetate fraction from ethanol 30% extract 2; water extract 3; methanol extract and its fractions (dichloromethane, ethyl acetate, n-butanol, water) 4; ethanol extract of fermented and non-fermented sample 5; and methanol extract 6 | Rat ear edema and RBL cells 1, LPS-induced RAW 264.7 2,4,5; tert-butyl hydroperoxide (t-BHP)-induced RAW 264.7 RAW 264.7 4; LPS-induced C2C12 myotube cells 3; and PMA-induced mouse ear edema and erythema 6 | 1 [ |
|
|
Decreased production of NO 1,2,4,6,7,8,9, PGE2 2,4,6,7,9, and pro-inflammatory enzymes (iNOS and COX-2) 1,4,6,7,9 Inhibition of extracellular signal-regulated kinase (ERK) 1,4,6,9, c-Jun-N-terminal kinase (JNK) 4,6,9, p38 1,6,9, and NF-κB 1,4,6,9 activation Hindered cell migration and decreased MMP-2 and MMP-9 activity 3 Decreased population of T helper, T cytotoxic, granulocytes, eosinophil, and monocytes 5 Decreased production of TNF-α 5,6,7 IL-1β 5,6,7, IL-6 5,6,7, IL-4 5, IL-5 5, and IL-13 5 Elevated expression of hemeoxygenase 1 8 Decreased NO production and increased ROS scavenging activity 10 Suppression of ear edema and erythema formation 11 | Ethanol 70% extract 1,4,5; ethanol 85% extract 2; ethanol extract 3,6,7,10 and its fraction 3,6; methanol 80% extract and its fraction 8; combination of | LPS-induced RAW 264.7 1,2,4,6,8,9,10; PMA-induced HT1080 fibrosarcoma 3; concanavalin A-induced rat splenocytes 5; fine dust (FD)-induced RAW 264.7 7; and PMA-induced mouse ear edema and erythema 11 | 1 [ |
|
|
Decreased production of NO, IL-6, TNF-α, IL-1β, iNOS, and COX-2 via inhibition of NF-kB activation Decreased ear edema volume | Ethanol extract | LPS-induced RAW 264.7 and rat ear edema | [ |
|
| Suppression of mouse ear edema and erythema formation | Methanol extract | PMA-induced mouse ear edema and erythema | [ |
|
|
Decreased production of NO, IL-6, TNF-α, IL-1β, iNOS, and COX-2 1 Inhibition of NF-kB activation 1 Decreased ear edema volume 2 | Water extract 1; and ethanol extract 2 | LPS-induced RAW 264.7 1; and croton oil-induced rat ear edema 2 | 1 [ |
|
|
Decreased production of IL-12 p40, IL-6, and TNF-α Inhibition of NF-kB nuclear translocation and IkB degradation 1,2 Decreased production of NO, PGE2, iNOS, COX-2, TNF-α, and IL-1β 2 Suppression of PI3K/Akt and ERK phosphorylation and increased nuclear factor erythroid-2-related factor 2 (Nrf2) and hemeoxygenase-1 expression 2 | Ethanol 70% extract 1,2 | CpG-DNA-induced bone marrow-derived macrophages (BMDMs) and bone marrow-derived dendritic cells (BMDCs) from C57BL/6 mice 1; and LPS-induced RAW 264.7 2 | 1 [ |
|
|
Decreased production of NO, IL-6, IL-1β, TNF-α, iNOS, and COX -2 via inhibition of NF-kB p65 activation 1 Decreased ear edema volume 1 Suppression of mouse ear edema and erythema formation 2 | Ethanol extract 1; and methanol extract 2 | LPS-induced RAW 264.7 and rat ear edema 1; and PMA-induced mouse ear edema and erythema 2 | 1 [ |
|
|
Decreased NO and PGE2 production, iNOS and COX-2 expression (protein and mRNA), IL-1β and IL-6 expression (mRNA) 1 Decreased production of IL-6, TNF-α, and interferon (IFN)-γ in serum and lymphocyte 2 Improved arthritis score, edema condition, and histology of the knee joint 2 Suppressed MMP-1 expression via inhibition of activator protein (AP)-1 activation and its binding to MMP-1 promoter 3 Decreased production of serum IL-2, TNF-α, and IL-1β 4 Suppression of p38 and JNK phosphorylation 5 | Ethanol 80% extract and its fraction (hexane, CH2Cl2, EtOAc, BuOH, and water) 1; ethanol 70% extract 2; ethyl acetate fraction of ethanol extract 3,5; and methanol extract 4 | LPS-induced RAW 264.7 1; Collagen-induced arthritis DBA/1J mice 2; UVB-induced HaCaT keratinocytes 3,5; and STZ-induced hepatic injury in Wistar rats 4 | 1 [ |
|
|
Decreased production of histamine and β-hexosaminidase in PMA-induced rat peritoneal mastocyte 1 Decreased production of IL-8 and TNF-α in A23187-induced HMC-1 1 Inhibition of NF-kB activation in TNF-α-induced 293T cells 1 Decreased iNOS expression via inhibition of MAPKs activation 2 Decreased NO production and increased ROS scavenging activity 3 | Methanol extract 1,2; and ethanol extract 3 | PMA-induced rat peritoneal mastocyte, A23187-induced HMC-1/human mast cell, and TNF-α-induced 293T cells 1; β-amyloid protein (Aβ)-induced HT-22 mouse neuronal cells 2; and LPS and H2O2-induced RAW 264.7 3 | 1 [ |
|
|
Decreased iNOS expression via inhibition of MAPKs activation 1 Suppression of mouse ear edema and erythema formation 2 | Methanol extract 1,2 | β-amyloid protein (Aβ)-induced HT-22 mouse neuronal cells 1; and PMA-induced mouse ear edema and erythema 2 | 1 [ |
|
| Suppression of NO and iNOS production | Aqueous extract of sample fermented by | LPS-induced RAW 264.7 | [ |
|
|
Enhanced production of serum IL-2, IL-4, and IL-10 Decreased production of serum IL-6, IL-1β, and TNF-α | Water extract | N-methyl-N′-nitro-nitrosoguanidine | [ |
Note: References followed by an asterisk (*) used samples from a tropical area. The superscripted numbering of reference, model, tested compund, and observed response in the same row are related to one another. This superscripted numbering is discontinous between rows and only applied to the same row.
Studies on the anti-inflammatory activity of Sargassum crude sulfated polysaccharides (CSP) and their fractions.
| Sample | Observed Response | Tested Compound | Model | Ref |
|---|---|---|---|---|
|
| ||||
|
|
Suppressed edema formation, neutrophil migration, and peritoneal exudate production 1,2 Improved serum lipid profile, and decreased TNF-α, CRP, fibrinogen, iNOS, NO, COX-2, and lysosomal enzymes production 3 | CSP 2,3; and fraction of CSP (Fr IV) 1 | Carrageenan-induced rat paw edema, carrageenan-induced peritonitis, and Freund’s adjuvant-induced arthritis 1,2; and hypercholesterol diet-induced rat dyslipidemia 3 | 1 [ |
|
|
Decreased production of NO and iNOS Inhibition of p38, JNK, ERK, and NF-kB activation | CSP and its fraction (1193.2, 864.4, 386.1 kDa, 55.9, 15.4, and 1.9 kDa) | LPS-induced RAW 264.7 | [ |
|
|
Increased PMNL viability Decreased production of cathepsin D, nitrate, and TNF-α. | CSP | TPA (12- O- Techanoyl 13—Myristate)-induced polymorphonuclear leukocytes (PMNL) | [ |
|
| Decreased production of NO and TNF-α | CSP | LPS-induced lymph macrophage | [ |
|
| Suppressed paw edema formation | CSP | Carrageenan-induced rat paw edema | [ |
|
| Decreased production of NO 1,2, PGE2, TNF-α, IL-1β, and IL-6 1 | CSP 1,2 | LPS-induced RAW 264.7 | 1 [ |
|
| Decreased production of NO, TNF-α, and COX-2 | Different fraction of water-soluble polysaccharide extracts (not only sulfated form) | LPS-induced RAW 264.7 | [ |
|
|
Decreased production of TNF-α, IL-1β, IL-6 1,2, and MCP-1 2 Decreased NO production | Different fraction of water-soluble polysaccharide extracts (not only sulfated form) 1,2,3 | LPS-induced peripheral blood mononuclear cells 1,2; and LPS-stimulated promyelocyticleukemic cells 3 | 1 [ |
|
| ||||
|
|
Decreased production of NO, PGE2, and pro-inflammatory cytokines 1,2,3 Inhibition of NF-kB activation 1,2 and phosphorylation of p-38 and ERK1/2 2 Decreased NO production in LPS-induced zebra fish 1 | Fraction of CSP yielded from membrane filtration (<5 kDa (f1), 5–10 kDa (f2), 10–30 kDa (f3), and >30 kDa (f4)) 1; and CSP resulted from Celluclast enzyme digestion 2, CSP and its fractions (Q Sepharose Fast Flow column) 3 | LPS-induced RAW 264.7 1,2,3; and LPS-induced zebra fish 1 | 1 [ |
|
|
Hindered formation of erythema and ear edema, and decreased neutrophil infiltration 1 Decreased production of MPO, NO, IL-1β, IL-6, and TNF-α in rat ear1 and RAW 264.7 2 | CSP | Arachidonic acid-induced rat ear edema 1; and LPS-induced RAW 264.7 2 | 1 [ |
Note: References followed by an asterisk (*) used samples from tropical area. The superscripted numbering of reference, model, tested compund, and observed response in the same row are related to one another. This superscripted numbering is discontinous between rows and only applied to the same row.
The anti-inflammatory activity of Sargassum purified compounds and their mechanisms in modulating inflammation (lipid-soluble compounds).
| Compound | Source | Modulation of Inflammation | Ref |
|---|---|---|---|
|
| |||
| Fucosterol |
| Suppression of COX-2, PGE2, TNF-α, and IL-6 production via the inhibition of NF-kB activation and MAPK group phosphorylation | [ |
| Sargachromenol |
| Suppression of adhesion molecules (VCAM-1, and ICAM-1) and chemotactic cytokine (MCP-1) production via inhibition of IKK-β - Ikβ phosphorylation, and NF-kB nuclear translocation in TNF-α-induced HUVECs | [ |
|
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), PGE2, NO, COX-2, and iNOS production via inhibition of Ikβ degradation in LPS-induced RAW 264.7 | [ | |
|
| Suppression of MMP-1, -2, and -9 via inhibition of AP-1 activation (c-Jun and c-Fos) in UVA-induced human derman fibroblast | [ | |
|
| Inhibition of JNK and ERK phosphorylation and increased ROS scavenging activity in UVB-induced HaCaT keratinocytes | [ | |
| Sargaquinoic acid |
| Suppression of adhesion molecules (VCAM-1, and ICAM-1) and chemotactic cytokine (MCP-1, and IL-8) production via inhibition of Ikβ degradation in TNF-α-induced HUVECs | [ |
|
| Suppression of iNOS and NO production via inhibition of Ikβ degradation, NF-kB nuclear translocation, and JNK1/2 phosphorylation in LPS-induced RAW 264.7 | [ | |
| Sargahydroquinoic acid |
| Suppression of MMP-2/-9 expression via inhibition of NF-kB nuclear translocation, Ikβ degradation, and AP-1 activation in TNF-α stimulated HaCaT cells | [ |
| Sargachromanol D |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), PGE2, NO, COX-2, and iNOS production via inhibition of p65 and Ikβ-α phosphorylation in LPS-induced RAW 264.7 | [ |
| Sargachromanol E |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), PGE2, NO, COX-2, and iNOS production via inhibition of MAPKs group phosphorylation (JNK, ERK, and p38) LPS-induced RAW 264.7 | [ |
| Sargachromanol G |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), PGE2, NO, COX-2, and iNOS production via inhibition of IkB-α, NF-κB (p65 and p50), and MAPK (ERK1/2, JNK, and p38) phosphorylation in LPS-induced RAW 264.7 | [ |
| Suppression of osteoclastogenic factor (PGE2, COX-2, IL-6, OPG, and RANKL) via inhibition of IkB-α, NF-κB (p65 and p50), and MAPKs (ERK1/2, JNK, and p38) phosphorylation in IL-1β-induced MG-63 osteoblast cells | [ | ||
| Isoketochabrolic acid (IKCA) |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), PGE2, NO, COX-2, and iNOS production in LPS-induced RAW 264.7 | [ |
| Tuberatolide B |
| Suppression of NO, PGE2, IL-6, IL-1β, iNOS, and COX-2 production via inhibition of NF-κB (p65) and MAPK (ERK1/2, JNK, and p38) phosphorylation, and IkB degradation LPS-induced RAW 264.7 | [ |
| Isonahocol E3 |
| Suppression of IL-6, IL-8, and TNF-α production, and MMP gene expression via inhibition of ERK phosphorylation in ET-1-induced human keratinocytes | [ |
| Loliolide |
| Suppression of NO production in LPS-induced RAW 264.7 | [ |
|
| |||
| Fucoxanthin |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), PGE2, NO, COX-2, and iNOS production in LPS-induced RAW 264.7 | [ |
| Apo-9′-fucoxanthinone |
| Suppression of NO 1,2, PGE2, proinflammatory cytokines (TNF-α, IL-6, and IL-1β), iNOS, and COX-2 production via inhibition of NF-κB (p65) and MAPK (ERK1/2, JNK, and p38) phosphorylation, and IkB degradation in LPS-induced RAW 264.7 1 | [ |
| Suppression of NO and PGE2 production via inhibition of Ikβ degradation in LPS-induced RAW 264.7 | [ | ||
| Suppression of pro-inflammatory cytokines (IL-12 p40, TNF-α, and IL-6) and iNOS production via inhibition of ERK phosphorylation and AP-1 translocation in CpG DNA-induced BMDMs (bone marrow-derived macrophages) and BMDC (bone marrow-derived dendritic cells) | [ | ||
| Suppression of IgE, IL-4, interferon- gamma, and TNF-α production, and lymph node size in atopic dermatitis rats | [ | ||
|
| |||
| Aryl polyketide lactone |
| Direct inhibition of 5-LOX, COX-2, and COX-1 enzymes (in vitro) | [ |
| Grasshopper ketone |
| Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), NO, COX-2, and iNOS production via inhibition of p65 NF-κB nuclear translocation and MAPK (ERK1/2, JNK, and p38) phosphorylation in LPS-induced RAW 264.7 | [ |
Note: References followed by an asterisk (*) used samples from tropical area. The superscripted numbering as listed in reference and modulation of inflammation in the same row are related to one another. This superscripted numbering is discontinous between rows and only applied to the same row.
Anti-inflammatory activity of Sargassum purified compounds and their mechanism in modulating inflammation (water-soluble compounds).
| Compound | Source | Modulation of Inflammation | Ref |
|---|---|---|---|
|
| |||
| Purified FCSPs (fucoidan) |
| Direct inhibition of 5-LOX, COX-2, and COX-1 enzymes (in vitro). | [ |
|
| Increased secretion of anti-inflammatory cytokines (IL-2, IL-4, and IL-10) and suppression of pro-inflammatory cytokines (IL-6 and TNF-α) production in MNNG-induced gastric cancer rats. | [ | |
|
| A combination of oligofucoidan (LMF) and fucoxanthin resulted in enhancement of the intestinal epithelial barrier and immune function against LPS stimulation through suppression of IL-1β and TNF-α production and increased secretion of IL-10 and IFN-γ in CaCo2 cells co-cultured with | [ | |
|
| Decreased NO production (IC50 = 40 μg/mL) via inhibition of the NF-κB and MAPK (ERK and p38) signaling pathways in LPS-stimulated RAW 264.7 cells. | [ | |
| Alginic acid |
| Suppression of PGE2, proinflammatory cytokines (TNF-α, IL-6, and IL-1β), and COX-2 production via inhibition of NF-κB (p65) nuclear translocation and MAPK (ERK1/2, JNK, and p38) phosphorylation in CFD (Chinese fine dust)-induced HaCaT keratinocytes. | [ |
|
| Suppression of COX-2, 5-LOX, MPO, xanthine oxidase (XO), ceruloplasmin, rheumatoid factor, CRP, pro-inflammatory cytokines, and lysosomal enzymes in type-2 collagen-induced rat arthritis. | [ | |
| Suppression of COX-2, 5-LOX, MPO, XO, ceruloplasmin, rheumatoid factor, and CRP production, and enhancement of antioxidant enzymes activity in Freund’s complete adjuvant-induced rat arthritis. | [ | ||
|
| |||
| Phlorotannin |
| Suppression of ROS production in PMA-induced neutrophil and suppression of PGE2, COX-1, and COX-2 expression in A23187-induced erythrocytes. | [ |
|
| Suppression of NO production in LPS-induced RAW 264.7 and direct scavenging of NO in a cell-free system. | [ | |
Note: References followed by an asterisk (*) used samples from tropical area. The superscripted numbering as listed in reference and modulation of inflammation in the same row are related to one another. This superscripted numbering is discontinous between rows and only applied to the same row.
Figure 1Phylogenetic relationship of genus Sargassum, implemented by the maximum likelihood method based on internal transcribed spacer (ITS-2) gene alignment. The numbers at each node represent the bootstrap value.
Figure 2Chemical structures of several terpenoid compounds of Sargassum sp.: (a) fucosterol [156], (b) sargachromenol [126], (c) sargaquinoic acid [126], (d) sargachromanol D [157], (e) sargachromanol E [158], (f) sargachromanol G [159], (g) isoketochabrolic acid [125], (h) loliolide [160], (i) tuberatolide B [161], (j) isonahocol E3 [128] “Reprinted from European Journal of Pharmachology, 720/1-3, Sah et al., Novel isonahocol E3 exhibits anti-inflammatory and anti-angiogenic effects in endothelin-1-stimulated human keratinocytes, 205-211, Copyright (2013), with permission from Elsevier”, and (k) sargahydroquinoic acid [162].
Figure 3The chemical structures of fucoxanthin and its derivatives of Sargassum sp.: (a) all-trans-(6′R)-fucoxanthin [165], (b) 9-cis-(6′R)-fucoxanthin [117], (c) 13′-cis-(6′R)-fucoxanthin [117], (d) 13-cis-(6′R)-fucoxanthin [117] “Reprinted from Food and Chemical Toxicology, 50/9, Heo et al., Anti-inflammatory effect of fucoxanthin derivatives isolated from Sargassum siliquastrum in lipopolysaccharide-stimulated RAW 264.7 macrophage, 3336-3342, Copyright (2012), with permission from Elsevier”, and (e) apo-9′-fucoxanthinone [166].
Figure 4Chemical structures of other lipid-soluble compounds of Sargassum sp.: (a) 4-(8-ethyl-tetrahydro-7-oxo-2H-pyran-5-yl)-propyl-4’-methyl benzoate, (b) methyl-2-(12-oxo-7-phenyl-8-vinyl-1-oxa-4,9- cyclododecadien-3-yl)-acetate [144] “Reprinted from Food Research International, 100, Maneesh A. and Chakraborty K., Unprecedented antioxidative and anti-inflammatory aryl polyketides from the brown seaweed Sargassum wightii, 640-649, Copyright (2017), with permission from Elsevier”, and (c) grasshopper ketone [168].
Figure 5Chemical structures of the polysaccharide compounds of Sargassum sp.: (a) Alginic acid [172] and (b) sulfated polygalactopyanosil fucopyranan (an example of purified fucose-containing sulfated polysaccharides (FCSPs)) [136] “Reprinted by permission from [Springer Nature Customer Service Centre GmbH]: [Springer Nature] [Journal of Applied Phycology] [Pharmacological potential of sulfated polygalactopyranosyl-fucopyranan from the brown seaweed Sargassum wightii, Maneesh A. And Chakraborty K), [COPYRIGHT] (2018)”.
Figure 6Chemical structures of the phenolic compounds of Sargassum sp.: (a) Phloroglucinol (a monomer of phlorotannin), (b) tetraphloretol B (an example of the phlorethol group), (c) tetrafuhalol A (an example of the fuhalol group), and (d) fucodiphlorethol A (an example of the fucophlorethol group) [143].
Figure 7The inflammatory signaling pathway and the resulting downstream responses. Signs of and show the potential modulation of Sargassum bioactive compounds on the inflammatory response, including (1) the inhibition of NF-kB and MAPK activation, (2) the inhibition of pro-inflammatory enzymes PLA2, 5-LOX, COX-2, iNOS, and (3) the direct scavenging of radical species. This illustration was created by the author using Biorender.com.